Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

24.37 +0.08 (+0.33%)

Official Closing Price Updated: 7:00 PM EDT, Jun 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. ↗

June 06, 2026

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Via The Motley Fool

Topics Intellectual Property

Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems ↗

June 06, 2026

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

Via The Motley Fool

Topics Intellectual Property

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

June 06, 2026

From Pfizer Inc.

Via Business Wire

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data ↗

June 05, 2026

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where...

Via MarketBeat

2 Cash-Producing Stocks Worth Your Attention and 1 Facing Headwinds

June 05, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 ↗

June 04, 2026

Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting...

Via MarketBeat

Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? ↗

June 04, 2026

Durability, not yield, is the deciding factor.

Via The Motley Fool

Avascular Necrosis Market Size, Industry Share By 2035 ↗

June 04, 2026

The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,

Via Talk Markets

Topics Economy

3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

June 03, 2026

These stocks pay between 4.2% and 6.7% in dividends.

Via The Motley Fool

Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗

June 03, 2026

Whichever one you choose, you'll need patience before you can see solid returns.

Via The Motley Fool

Topics Intellectual Property

Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 ↗

June 03, 2026

It is finally bouncing back after several challenging years.

Via The Motley Fool

3 Large-Cap Stocks with Solid Fundamentals

June 03, 2026

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Via StockStory

How to Recession-Proof Your Retirement Before the Second Half of 2026 ↗

June 02, 2026

You should consider these strategies if you can't afford to wait out another market crash.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

3 Dividend Stocks to Buy and Hold Forever ↗

June 02, 2026

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

Via The Motley Fool

Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗

June 01, 2026

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 01, 2026

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

Via The Motley Fool

Topics Intellectual Property

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗

June 01, 2026

This little-discussed pipeline program could prove to be a big success.

Via The Motley Fool

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

June 01, 2026

From Pfizer Inc.

Via Business Wire

Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed? ↗

June 01, 2026

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Via The Motley Fool

Topics Economy

1 Healthcare Stock with Promising Prospects and 2 We Find Risky

June 01, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...

Via StockStory

3 Cash-Producing Stocks Worth Your Attention

June 01, 2026

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ...

Via StockStory

Is Pfizer Stock a "Value Trap" or a Generational Opportunity? ↗

May 31, 2026

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Via The Motley Fool

Topics Intellectual Property

How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat Cancers ↗

May 31, 2026

Pfizer said Sunday its Braftovi-tied regimen nearly doubled the time colon cancer patients lived without getting sicker.

Via Investor's Business Daily

Topics Stocks

Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026

From Pfizer Inc.

Via Business Wire

Thriving in the Age of Overwhelm ↗

May 30, 2026

Why do so many people feel overwhelmed right now? And what can investors do about it?

Via The Motley Fool

Why Wall Street Is Dead Wrong About This Popular Stock ↗

May 30, 2026

Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term.

Via The Motley Fool

Topics Intellectual Property

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026

From Pfizer Inc.

Via Business Wire

Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29, 2026

From Pfizer Inc.

Via Business Wire

Addiction Treatment Market Size, Demand, Growth By 2035 ↗

May 29, 2026

The most recent research report on the "Addiction Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

Via Talk Markets

Topics Economy

Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies ↗

May 29, 2026

Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.